Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 17/20 | 0.47 |
| ▸ | FNTB | P49356 | 17/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 17/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222091 | 0.85 | FNTA (0.47) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL7220637 | 0.84 | FNTA (0.47) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7673750 | 0.83 | FNTA (0.44) | CYP17A1CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL7710770 | 0.81 | AR (0.39) | CYP17A1CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL7704750 | 0.78 | S1PR3 (0.39) | CYP17A1CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL7566587 | 0.78 | FNTB (0.42) | FNTAFNTBPGGT1BRORCCYP11B1 | |
| SCHEMBL7736904 | 0.78 | S1PR3 (0.42) | CYP17A1CYP3A4FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL7220321 | 0.76 | FNTA (0.41) | CYP17A1CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL7589567 | 0.75 | FNTB (0.39) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL7701717 | 0.75 | FNTB (0.39) | FNTAFNTBPGGT1BRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6297239-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | CYP17A1 1346/4885CYP3A4 1528/4885FNTA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.